Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Canada Postdoctoral Research Award (CPRA) program

Direct Payment

$140,000.00

Impaired RNA editing as a driver of neuroinflammation in Alzheimer's disease

FY 2025-26

Summary
Alzheimer's disease is a devastating brain disorder that affects millions worldwide, leading to memory loss and cognitive decline. While it is clear that genetics plays a major role in the disease, exactly how specific genetic changes contribute remains a critical unanswered question. Recent studies suggest that the brain's immune cells, called microglia, may become overactive in Alzheimer's, triggering harmful inflammation that damages neurons. This project investigates how certain genetic changes may lead to this microglial overreaction by focusing on an intriguing cellular process called RNA editing. Normally, an enzyme called ADAR1 acts like a spell-checker, editing RNA to prevent the immune system from mistaking the body's own RNA for that of a virus. But in some people with Alzheimer's, genetic evidence suggests reduced RNA editing activity, especially in microglia. As a result, the immune system's sensors, particularly the antiviral protein MDA5, may wrongly identify the brain's own RNA as a threat, leading to excessive and damaging inflammation. Our study aims to uncover how defects in RNA editing disrupt microglial function and contribute to brain inflammation and Alzheimer's pathology. To do this, we will analyze human brain samples to examine patterns of gene activity and inherited genetic differences, use advanced cellular models such as human brain cells grown from stem cells, and reduce ADAR1 activity in mice to observe its impact on brain health. Ultimately, this work could reshape how we understand Alzheimer's by revealing how some individuals may be genetically prone to an inflammation-driven form of the disease. More importantly, it could open the door to entirely new therapies that precisely target RNA editing to calm harmful inflammation and help protect brain health.
Program
Canada Postdoctoral Research Award (CPRA) program
Location
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
537823
Name
Dabouz Rabah
Region
California
Country
United States of America
Orgtype
Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Canada Postdoctoral Research Award - A
Projecttitle
Impaired RNA editing as a driver of neuroinflammation in Alzheimer's disease
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Alzheimer'S Disease; Human Genetics; Microglia; Neuroinflammation; Rna Editing
Abstract
Alzheimer's disease is a devastating brain disorder that affects millions worldwide, leading to memory loss and cognitive decline. While it is clear that genetics plays a major role in the disease, exactly how specific genetic changes contribute remains a critical unanswered question. Recent studies suggest that the brain's immune cells, called microglia, may become overactive in Alzheimer's, triggering harmful inflammation that damages neurons. This project investigates how certain genetic changes may lead to this microglial overreaction by focusing on an intriguing cellular process called RNA editing. Normally, an enzyme called ADAR1 acts like a spell-checker, editing RNA to prevent the immune system from mistaking the body's own RNA for that of a virus. But in some people with Alzheimer's, genetic evidence suggests reduced RNA editing activity, especially in microglia. As a result, the immune system's sensors, particularly the antiviral protein MDA5, may wrongly identify the brain's own RNA as a threat, leading to excessive and damaging inflammation. Our study aims to uncover how defects in RNA editing disrupt microglial function and contribute to brain inflammation and Alzheimer's pathology. To do this, we will analyze human brain samples to examine patterns of gene activity and inherited genetic differences, use advanced cellular models such as human brain cells grown from stem cells, and reduce ADAR1 activity in mice to observe its impact on brain health. Ultimately, this work could reshape how we understand Alzheimer's by revealing how some individuals may be genetically prone to an inflammation-driven form of the disease. More importantly, it could open the door to entirely new therapies that precisely target RNA editing to calm harmful inflammation and help protect brain health.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Dabouz, Rabah
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~